Method for the normalization of sexual response and amelioration of long term genital tissue degradation

Abstract

The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The preferred central nervous system sexual response initiator is apomorphine or a pharmaceutically acceptable acid addition salt thereof.

Description

TECHNICAL FIELD [0001] The present application relates to pharmaceutical formulations and to medical methods of treatment. More particularly, the present invention concerns the use of a compound which acts as a central nervous system sexual response initiator for the normalization of the timing of sexual response in humans and for the prophylaxis or treatment of long-term damage to genital organ. BACKGROUND OF THE INVENTION [0002] Proper sexual functioning in men and women depends upon a combination of steps including 1) establishment of the appropriate anticipatory mental set (“desire”), 2) effective vasocongestive arousal (an erection in the male sufficient for vaginal penetration and, in the female, clitoral erection, vaginal engorgement and lubrication), and 3) orgasm. The timing of these steps between partners engaging in sexual relations is mediated by one or more of several compounds which act in neurological pathways in the mesencephalon or mid-brain. These pathways include ...

AI Technical Summary

Benefits of technology

[0012] It has been found, in accordance with one embodiment of the present invention that the acute administration of an agent which acts upon mid-brain dopaminergic, serotonergic, oxytocinergic or nitroxidergic pathways to initiate mammalian sexual response in an amount which is insufficient to produce effective vasocongestive arousal, but is sufficient to produce increased genital vasodilation, acts to normalize the timing of sexual response between sexual partners.

Problems solved by technology

Timing of the various aspects or parameters of sexual response between partners engaging in sex is important and often mis-matched due to psychological, or sometimes biogenic, dysfunction in one or both of the partners.

Even in sex partners having sexual responses deemed to fall within the norm, there is a frequent mis-match of the timing of response.

Most women are unable to reach orgasm within this short period of time, one cause of the problem of inappropriate timing of sexual response between sexual partners, even when the sexual responses of both are within physiological norms.

The problem of inappropriate timing of sexual response is not limited to the human species, but occurs also in lower mammals as well, for example, in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats.

Images